Introduction
Dendritic cells (DCs) are professional antigen-presenting cells specialized in the initiation of immune responses and with the unique capacity to activate naïve T cells. [1] [2] [3] [4] Normally, DCs can be found in two states, as immature DCs (iDCs) with the capacity to induce T-cell tolerance, or as mature DCs (mDCs), which are immunogenic and promote T-cell activation. 2, 3, 5, 6 iDCs reside in most peripheral tissues where they take up antigens continuously and transport them to draining lymph nodes for presentation to T cells in a tolerogenic manner. However, during an infection, pathogen-associated molecular pattern (PAMP) recognition promotes DC maturation and upregulation of the surface expression of costimulatory molecules. 2, 3, 5, 6 In the lymph nodes, mDCs present processed antigens to specific T cells in the presence of highly expressed surface costimulatory molecules in order to trigger T-cell immunity.
The generation of immune complexes (ICs) occurs as the physiological consequence of the encounter of antibodies with their cognate antigens. This process may occur in the setting of an immune response to an invading pathogen, but when a self-antigen is recognized, IC formation is also believed to underlie autoimmune pathogenesis. [7] [8] [9] [10] The Fc portion of the antibody component of the IC interacts with Fc receptors (FccRs), which are expressed by a wide range of immune cells. 3 
Summary
Dendritic cells (DCs) play a pivotal role in the interface between immunity and maintenance of peripheral tolerance. The capture of immunoglobulin G (IgG)-containing immune complexes (ICs) by low-affinity Fcc receptors (FccRs) expressed on DCs may influence the immunogenicity/ tolerogenicity of these cells, depending on the activating/inhibitory potential of FccRs. Because of the key role that low-affinity FccRs play in determining the magnitude of the response in IC-driven inflammation, these receptors are likely to play a role in autoimmune diseases, such as systemic lupus erythematosus (SLE). To evaluate if an altered expression of costimulatory molecules and/or FccRs could account for disease severity, we evaluated the expression of these molecules on immature and mature DCs derived from peripheral blood monocytes of SLE patients and healthy donors. Our results show an increased expression of the costimulatory molecules CD40 and CD86. Furthermore, the ratio of CD86/CD80 is higher in SLE patients compared with healthy donors. Conversely, while the expression of activating FccRs was higher on DCs from SLE patients, expression of inhibitory FccRs was lower, compared with DCs obtained from healthy donors. As a result, the activating to inhibitory FccR ratio was significantly higher in DCs from SLE patients. The altered ratio of activating/inhibitory FccRs on mature DCs showed a significant correlation with the activity of SLE, as determined by the SLE Disease Activity Index (SLEDAI) score. We postulate that the increased ratio of activating/ inhibitory FccRs expressed on DCs from SLE patients can contribute to the failure of peripheral tolerance in the IC-mediated phase of autoimmune pathogenesis.
Keywords: dendritic cells; Fcc receptors; systemic lupus erythematosus major types of FccRs have been described, either activating receptors or inhibitory receptors, depending on the immunotyrosine motifs transducing intracellular signalling. 9, 11, 12 The balance of FccR expression on DCs can determine two alternative phenotypes, the first corresponding to a mature and activating state capable of inducing T-cell immunity, and the second corresponding to an immature state inducing T-cell tolerance. 3, 9, 11 As a result, the predominant receptor type determines the outcome of IC-induced DC response and T-cell activation. FccRs are important effector molecules of humoral immunity and they are involved in the pathogenesis of autoimmune diseases characterized by the accumulation of ICs, such as systemic lupus erythematosus (SLE). 8, 10, 13, 14 3, 16, 17 Thus, the balance of activating/ inhibitory low-affinity FccRs on DCs may determine their immunogenic/tolerogenic potential. 2, 3 SLE is an autoimmune disorder characterized by autoantibody production and IC formation and deposition, which results in immunologically mediated tissue injury. 13, [18] [19] [20] Because DCs play a pivotal role at the interface of immunity and peripheral tolerance, 2, 3 and because of the key role that low-affinity FccRs play in determining the magnitude of the response in IC-driven inflammation and autoimmune diseases, 7, 9, 13, 21, 22 we set out to examine the expression of low-affinity FccRs on DCs derived from peripheral blood monocytes of SLE patients and healthy donors. In addition, we addressed the question as to whether the expression of costimulatory molecules is altered in DCs from SLE patients. We found that DCs derived from SLE patients (SLE-DC) show an increase in the expression of costimulatory molecules, which is consistent with previous studies. 23, 24 In addition, while activating FccRs also show an increase in expression, inhibitory FccRs are expressed at a lower level when compared with healthy donors (healthy-DC). Remarkably, the ratios of CD86/CD80 and of activating/inhibitory FccRs are higher on SLE-DC than on healthy-DC and show a significant correlation with the SLE Disease Activity Index (SLEDAI) score. Our results highlight a potential mechanism by which DCs play a pivotal role in the progression of SLE.
Materials and methods

Antibodies and reagents
Fluorescein isothiocyanate (FITC)-conjugated monoclonal antibodies (mAbs) against human leucocyte antigen (HLA)-DR, CD16 (clone 3G8), CD32 (clone FLI8Á26) and anIgG-c1 isotype-matched-control; phycoerythrin (PE)-conjugated mAbs against CD11c, CD80 (clone L307Á4) and an IgG-c1 isotype-matched-control; and allophycocyanin (APC)-conjugated mAbs against CD86 and an IgG-c1 isotype-matched control were all purchased from Becton Dickinson (San Jose, CA). FITC-conjugated and PE-conjugated mAb anti-CD32 (clone 7Á3) were respectively obtained from Research Diagnostics and from Fitzgerald Industries International Inc. (Concord, MA). AlexaFluor488-conjugated mAb anti-CD32a (clone IV.3) and antiCD32b (clone 2B6) were obtained from MacroGenics, Inc. (Rockville, MD). Lipopolysaccharide (LPS) was purchased from Sigma (St Louis, MO). Recombinant human interleukin-4 (IL-4) and recombinant human granulocytemacrophage colony-stimulating factor (GM-CSF) were purchased from Prospec-Tany Technogene Ltd (Rehovot, Israel).
Patients
In this cross-sectional study, 31 non-selected SLE patients treated at Hospital Clínico de la Pontificia Universidad Cató lica de Chile were analyzed. Exclusion criteria were pregnancy; patients undergoing dialysis or who were severely ill (such as those in the intensive care unit or who were haemodynamically unstable); patients with infections; and patients with drug-induced leucopoenia or anaemia. Patient characteristics are summarized in Table 1 . As controls we included 20 healthy donors. In both the SLE and healthy-donor groups, 90% were women and the average age was 39 ± 14 years and 28 ± 5 years, respectively. In addition, we included three male liver-transplanted patients undergoing treatment with prednisone and cyclosporine (average age 58 ± 4 years). An informed consent form, obtained in accordance with the Ethics Committee of the School of Medicine, was signed by each patient before the collection of peripheral blood samples.
Generation of monocyte-derived DCs
Human peripheral blood mononuclear cells (PBMCs) were separated from whole blood using the standard Ficoll centrifugation method. Monocytes were obtained using the adherence method. 25 Briefly, PBMCs (3 · 10 6 cells/ml) were incubated in serum-free XVIVO-15 medium (Bio-Whittaker, Walkersville, MD) supplemented with 1% autologous serum and 50 lg/ml of gentamycin (Calbiochem, San Diego, CA) (DC-medium) for 2 hr at 37°. Adherent cells were washed four times with prewarmed serum-free XVIVO-15 medium (Bio-Whittaker) and were then cultured in DC-medium at 37°. Monocytes were differentiated to iDCs over 6 days by the addition of 1000 U/ml of IL-4 and 1000 U/ml of GM-CSF on days 0, 3 and 5. DC maturation was triggered by the addition of LPS (5 lg/ml) for an additional 48 hr. DC immunophenotypes were confirmed by flow cytometry using specific antibodies against surface markers. The iDCs obtained were CD4 ) , 
Immunostaining
Cells were washed with phosphate-buffered saline (PBS), resuspended at 2 · 10 6 cells/ml (50 ll/tube), and incubated with FITC-, PE-and APC-conjugated antibodies for 30 min at 4°. FITC-, PE-and APC-conjugated isotype-matched antibodies were used as negative controls. Cells were washed with PBS, fixed with 1% formaldehyde in PBS and analyzed using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA).
Data analyses
Data analyses and statistical analysis were performed using PRISM 4 software (Graph Pad Software, Inc., San Diego, CA). For statistical analyses we used the unpaired Student's t-test. P values below 0Á05 were considered statistically significant. Correlation analyses were performed using the Spearman two-tailed correlation test with a confidence interval of 95%. Flow cytometry data were analyzed using CELLQUEST Pro Software (BD Biosciences) and WINMDI 2Á9 (http://facs.scripps.edu/software.html).
Results
DCs derived from SLE patients display altered expression of costimulatory molecules
Given that the expression of costimulatory molecules on the surface of DCs critically determines whether an interacting T cell is activated or tolerized, 2, 3, 26, 27 we analyzed the expression of CD40, CD80, CD83 and CD86 on the surface of immature and LPS-matured DCs obtained from 31 SLE patients (Table 1) and from 20 healthy donors. As expected, expression of these surface molecules was augmented, after LPS-promoted maturation, on the surface of both iDCs and mDCs (Fig. 1) . Although this trend did not reach statistical significance, CD40 was more highly expressed on iDCs and mDCs from SLE patients than on iDCs and mDCs from healthy donors (Fig. 1a) . However, another important costimulatory molecule, CD86, was expressed at a significantly higher level on both iDCs and mDCs of SLE patients, which is consistent with previous studies. 23, 24 Conversely, the levels of expression of CD80 and CD83 were significantly decreased on mDCs from SLE patients (Fig. 1c,d) , while only the level of expression of CD80 was significantly decreased on iDCs from SLE patients, compared with healthy donors (Fig. 1c,d ). Although CD80 and CD86 share structural similarities, it was recently suggested that these two molecules have contrasting effects on regulatory T cells (Tregs), 28 in that CD86 inhibits, while CD80 enhances, their suppressive effect. We hypothesized that in the setting of SLE, the Treg-suppressive function would be diminished, in part because of an unbalanced ratio of CD86/CD80 expression. As shown in Fig. 2 , the ratio of CD86/CD80 expression was approximately fivefold and sixfold higher on iDCs and mDCs, respectively, derived from SLE patients compared with healthy donors.
FccRs on DCs derived from SLE patients display an overactivation expression pattern
The expression of low-affinity FccRs is tightly linked to the maturation status of DCs, 3, 9 and these phenotypic changes have important functional consequences on the ability of DCs to stimulate either immunity or tolerance. We therefore compared the expression of low-affinity FccRs, including FccRIII (CD16), FccRIIa (CD32a) and FccRIIb (CD32b), on the surface of DCs from SLE patients and healthy donors. In both SLE patients and healthy donors, CD16 expression was very low on the surface of DCs (data not shown). Conversely, both CD32a and CD32b were highly expressed on the surface of iDCs obtained from SLE patients and controls, and in both groups, this expression was significantly decreased after LPS-induced maturation (Fig. 3a,b) . As shown in Fig. 3a , the expression of the activating receptor CD32a was slightly increased on iDCs and significantly increased on mDCs from SLE patients, whereas the expression of the inhibitory receptor CD32b was slightly lower on iDCs and significantly lower on mDCs from SLE patients compared with healthy donors (Fig. 3b) . It has been reported that the balance between activating and inhibitory lowaffinity FccRs is critical in determining the ability of DCs to promote immunity or tolerance. 29, 30 In order to The results show the mean ± standard error of the mean (SEM). *P < 0Á05; **P < 0Á01.
explore this concept in our model system, we evaluated the CD32a/CD32b ratio on iDCs and mDCs. Our analysis showed that this ratio was significantly increased in both iDCs and mDCs from SLE patients compared with healthy donors (Fig. 3c) . The observation that DCs obtained from liver-transplanted patients treated with immunosuppressive drugs showed no significant differences regarding the expression of FccRs or costimulatory molecules compared with the DCs from healthy donors (Fig. S1 ), supports the notion that the altered phenotype shown by DCs derived from SLE patients was not caused by an unspecific effect of the immunosuppressive treatment.
The altered ratio of activating/inhibitory FccRs is correlated with SLE disease activity To investigate, in more detail, the relevance of the altered ratio between the activating receptor CD32a and the inhibitory receptor CD32b, we examined whether higher ratios were associated with disease activity among a cohort of 20 SLE patients, as assessed using the SLEDAI score. 31 As shown in Fig. 4 , analysis of mDCs showed a significant correlation between the SLEDAI score and the CD32a/CD32b ratio (Fig. 4) , determined using the Spearman two-tailed test, with a Spearman r value of 0Á71 (P value of 0Á0006). By contrast, there was no significant correlation between the SLEDAI score and the CD32a/ CD32b ratio for iDCs (Fig. 4) , suggesting that mDCs could be more important in the progression of the disease.
Discussion
It is well accepted that maturation status is linked with the ability of DCs to induce either immunity or tolerance. 2, 3, 26, 27 Because classical costimulatory molecules and also low-affinity FccRs have recently been reported to be strongly involved in the maturation status of DCs, [2] [3] [4] 9, 22 we explored, in this study, the expression of these key molecules in patients with SLE.
Our results allowed us to conclude that the balance of activating/inhibitory low-affinity FccRs is augmented in DCs from SLE patients, which, in turn, suggests that these DCs can be more immunogenic or less tolerogenic than DCs from healthy donors. To our knowledge, this is the first report describing an imbalance of the expression of low-affinity FccRs on DCs derived from SLE patients.
While a genetic polymorphism on the promoter sequence of the CD32b gene was shown previously to cause a reduced expression of this receptor on B cells from SLE patients, 32 no such decrease was observed on iDCs from the same individuals. Our data extend this knowledge by showing significant differences on the expression of CD32a and CD32b on mDCs from SLE patients as compared with mDCs from healthy controls. It remains to be evaluated whether the differences in receptor expression seen in our patients are caused by polymorphisms in the promoter regions of CD32a and CD32b. This notion is supported by the observation that polymorphism in the promoter of the FCGR2B gene can increase the susceptibility to SLE. [33] [34] [35] In addition, our findings show a clear up-regulation of CD86 and a clear down-modulation of CD80 and CD83 on the surface of DCs from SLE patients, compared with healthy controls. It is noteworthy that the related costimulatory molecules CD80 and CD86 are deregulated in an opposite way in DCs from SLE patients, in light of the recent report that CD80 promotes costimulation for Tregs, whereas CD86 impairs activation of these cells. 28 Therefore, by assessing the CD86/CD80 ratio, it is possible to infer whether DCs have the potential to promote or to inhibit the suppressive function of Tregs. As DCs derived from our cohort of SLE patients showed an elevated CD86/CD80 ratio, our data suggest that, in conjunction with the activated state of DCs conferred by the high CD32a/CD32b ratio, these antigen-presenting cells may also be capable of inhibiting Treg function and further amplifying autoimmunity. Most strikingly, we found that higher ratios of the activating/inhibitory FccRs expressed on mature DCs were associated with higher disease activity, as measured by the SLEDAI score. This represents a potential biomarker for disease activity, and also suggests a target for therapeutic intervention. DC maturation therefore represents a plausible pathway for intervention, given that this cell type bears the most potential in both inducing and amplifying autoimmune pathogenesis, through its ability to license autoreactive naïve T cells.
In conclusion, our data demonstrate that DCs from SLE patients display an altered expression of key receptors on their surface, consisting of an increased ratio of activating/inhibitory low-affinity FccRs and an altered expression of costimulatory molecules, which could contribute to the loss of peripheral tolerance. These findings may help to elucidate, in greater detail, the emerging role of DCs in autoimmune diseases and could also help in the development of novel immunotherapeutic strategies for the treatment of IC-related diseases.
